• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

FINALLY - New Discount Program for Belviq

Quote








Anonymous said:
Interesting perspective, Only One thing your forgeting Kimosabe. and thats all the additional indications planned for Belviq, ever heard of smoking cessation? diabetes, obsessive compulsive disorders such as addictions of sexual nature and gambling etc?

exponential top and bottom line growth are the only big changes in store at 100 Tice. you can shake that to the bank.
Click to expand...

Whoa what you be smoking, I want some of that sh*t!

That stuff you be posting is nothing but pipe dreams.

Speaking of pipe, pass that smoking good crack over here dude.
Hey Arena you want some of this stuff?
 








Ya, that 3% net weight loss sure as heck didn't sell this piece of crap. We will soon be the 4th most effective weight loss drug. Why do you think we lowered the price? It sure wasn't to be nice or generous. It was because we have by far, the worst efficacy data. Stop drinking the kool ade, B sucks,
 








I would think the inflection point will come when Belviq gets to >60% of market share, then we can begn to see the light at the end of the tunnel. Contrave(26.1%) is still the brand to beat, so 48.3% just won't cut it. They need a herculean effort and no mistakes. The problem is timing is running out,
 








Let's see, both are bid with tons of interactions warnings and risks. Both have 3-4% net weight loss(0-6 combined in FDA mandated efficacy criteria of more than 5% vs placebo), 1/2 to 1/4 the other medication. Both are begging drs to rx solely on price, not clinical benefits. I guess with limited efficacy and increased risks, there isn't any way to sell on clinical benefits
 




Top Bottom
Back
Quote